Jevtana, Zytiga and Xtandi to push prostate cancer market to new heights
This article was originally published in Scrip
A recent influx of novel drugs to treat metastatic castration-resistant prostate cancer (mCRPC) will help drive strong growth in this market over the next ten years, a new forecast from Datamonitor has found.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.